Totals $.99 $.90 10 %
In the second quarter of 2008, Zyprexa sales totaled $1.240 billion, a 2 percent increase compared with the second quarter of 2007. U.S. sales of Zyprexa were essentially flat at $563.6 million. The impact from changes in both net selling prices and volume was negligible. Zyprexa sales in international markets increased 4 percent, to $676.2 million, driven by the favorable impact of foreign exchange rates, partially offset by lower prices and decreased demand. Demand outside the U.S. was unfavorably impacted by generic competition in Canada and Germany, offset by growth in Japan and several European markets.
For the second quarter of 2008, Cymbalta generated $654.4 million in sales, an increase of 26 percent compared with the second quarter of 2007. U.S. sales of Cymbalta increased 19 percent, to $542.8 million, driven primarily by higher demand. Sales outside the U.S. were $111.5 million, an increase of 80 percent, driven primarily by higher demand and, to a lesser extent, the favorable impact of foreign exchange rates. Higher demand outside the U.S. reflects both increased demand in established markets, as well as recent launches in new markets.
Gemzar sales totaled $440.1 million in the second quarter of 2008, an increase of 11 percent from the second quarter of 2007. Sales in the U.S. increased 11 percent, to $183.3 million, due to increased demand and higher prices, while sales outside the U.S. increased 12 percent, to $256.8 million, as a result of the favorable impact of foreign exchange rates.
For the second quarter of 2008, worldwide Humalog sales increased 22
percent, to $437.9 million. Sales in the U.S. increased 17 per
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved